Efficacy of TAK-559 in Treating Subjects With Type 2 Diabetes Mellitus

Status:
Completed

Trial end date:
2004-12-01

Target enrollment:

Participant gender:

The purpose of this study was to determine the safety and efficacy of TAK-559, once daily (QD), in Type 2 Diabetes subjects.

Phase 3

Takeda